Zollinger-Ellison syndrome
Peptic · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Gastrin-secreting neuroendocrine tumour (gastrinoma) causing severe acid hypersecretion with refractory/multiple peptic ulcers, diarrhoea and possible MEN1 association.
Red flags
- GI bleeding/perforation from ulcers
- Refractory ulcers despite standard therapy
- Diarrhoea with dehydration
- Features of MEN1
Assessment
Differential diagnosis
- H. pylori peptic ulcer disease
- NSAID-induced ulcers
- Crohn disease
- Idiopathic hyperacidity
- Refractory GORD
Investigations
- Fasting serum gastrin (off PPI where safe)
- Gastric pH/acid studies, secretin stimulation test
- Upper GI endoscopy (multiple/atypical ulcers)
- Chromogranin A, calcium/PTH (MEN1 screen)
- Somatostatin receptor imaging/CT for tumour localisation
Management
- Treat acute complications (bleeding/perforation) as usual
- High-dose proton pump inhibitor to control acid hypersecretion
- Confirm diagnosis with gastrin and provocative testing
- Screen for MEN1 (parathyroid, pituitary)
- Localise and stage the tumour
- Refer for surgical resection or somatostatin analogue therapy
Drugs & doses
High-dose proton pump inhibitor
Somatostatin analogue (octreotide/lanreotide)
Correct coexisting complications
Treat MEN1 components as needed
Disposition
Admit for complications; specialist endocrine/GI referral.
Complications & pitfalls
- Ulcer bleeding/perforation
- Metastatic gastrinoma
- Severe diarrhoea/malabsorption
Exam pearls
- Suspect with multiple or distal (jejunal) or recurrent ulcers
- PPIs raise gastrin - interpret levels with caution
- Up to a quarter of cases are part of MEN1
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.